Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives by ANDREW POLLACK

This is a blog post from Ari Pregen's Blog

By ANDREW POLLACK

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.

Published: September 29, 2014 at 4:00AM

from NYT Business Day http://ift.tt/1mCJi8r

http://aripregen.com

from WordPress http://ift.tt/106Kdny